Obviousness

Obviousness Analysis of US Patent 12447128

This analysis considers the obviousness of US patent 12447128 under 35 U.S.C. § 103, based on the prior art references explicitly cited within the patent's "Definitions" section.

Background of the Invention

US patent 12447128 addresses the challenge of formulating enzalutamide, an androgen receptor signaling inhibitor used for treating castration-resistant prostate cancer. The commercial product, XTANDI®, is a soft capsule containing liquid enzalutamide, requiring patients to take four 40 mg capsules daily for a 160 mg dose. The patent aims to provide a "suitable tablet of reasonable size" comprising the prescribed amount of enzalutamide, with "suitable and advantageous solubility and/or dissolution stability and absorption," as a more convenient alternative to soft capsules.

The patent's solution centers on solid formulations comprising amorphous enzalutamide in a solid dispersion with at least one concentration-enhancing polymer. These compositions are prepared by methods such as spray-drying or hot-melt extrusion, and are characterized by enhanced dissolution (e.g., higher Maximum Drug Concentration (MDC) and Area Under The Curve (AUC) in in vitro tests) and improved oral bioavailability in vivo. Preferred polymers include hydroxypropylmethylcellulose acetate succinate (HPMCAS), and preferred manufacturing methods include spray-drying.

Identified Prior Art

The US patent 12447128 explicitly references the following as prior art or relevant background:

1. U.S. Pat. No. 7,709,517: Discloses enzalutamide, its chemical structure, and its use as an agent for treating various cancers, including castration-resistant prostate cancer. It also describes crystalline enzalutamide.
2. US2002/0031547: Reports a solid dispersion of a sparingly soluble compound with a gel-forming water-soluble polymer (e.g., hydroxypropyl methylcellulose or hydroxypropylcellulose) to improve disintegration time and dissolution profile.
3. US2002/0009494: Discloses the use of hydroxypropylmethylcellulose acetate succinate (HPMCAS) in a pharmaceutical composition comprising a sparingly soluble compound, prepared by a spray drying method, to improve aqueous solubility and/or bioavailability.

Obviousness Analysis (35 U.S.C. § 103)

A person having ordinary skill in the art (POSA) in pharmaceutical formulation and drug delivery would be familiar with techniques to enhance the solubility and bioavailability of poorly soluble drugs, including the use of amorphous solid dispersions and various excipients.

Combination of U.S. Pat. No. 7,709,517 and US2002/0009494:

This combination provides strong grounds for an obviousness challenge to the central aspects of US patent 12447128.

• U.S. Pat. No. 7,709,517 establishes enzalutamide as a known drug with therapeutic utility. The problem statement in US12447128 itself indicates that enzalutamide, in its commercially available form, requires multiple liquid-filled capsules, implying a need for improved solid formulations. This strongly suggests that enzalutamide is a sparingly soluble compound, which would motivate a POSA to seek improved formulations.
• US2002/0009494 directly teaches the use of hydroxypropylmethylcellulose acetate succinate (HPMCAS) in a pharmaceutical composition comprising a sparingly soluble compound, prepared by a spray drying method, to improve aqueous solubility and/or bioavailability.

Motivation to Combine:
A POSA, tasked with developing a more convenient, effective solid oral dosage form for enzalutamide (known from '517), would immediately recognize the challenges associated with its likely poor aqueous solubility (inferred from the commercial liquid capsule formulation). The explicit teachings of US2002/0009494 provide a clear and direct motivation to combine the known drug enzalutamide with the specific polymer HPMCAS and the spray-drying method. The '494 publication precisely addresses the goal of improving aqueous solubility and bioavailability for sparingly soluble compounds, which aligns perfectly with the stated objective of US12447128.

Reasonable Expectation of Success:
Given the explicit teaching in US2002/0009494 that HPMCAS and spray-drying "improve aqueous solubility and/or bioavailability" for sparingly soluble compounds, a POSA would have a reasonable expectation of success in achieving these improvements for enzalutamide. It is well-established in the art that spray-drying a poorly soluble drug with a polymer often results in an amorphous solid dispersion, which is known to enhance dissolution rates compared to crystalline forms. The particular selection of HPMCAS is further supported by US12447128 itself, which describes HPMCAS as a "particularly desirable" and "concentration-enhancing polymer" that "performs particularly well." The specific quantitative enhancements in MDC, AUC, and Cmax, while perhaps significant, would be expected outcomes and/or achievable through routine optimization by a POSA following this established path. The goal of a single, higher-dose tablet would also be a natural consequence of achieving improved solubility and bioavailability, enabling higher drug loading per unit.

Addressing Arguments Against Obviousness:
US12447128 states that "Solubilization of a specific drug depends on its chemical structure and physical properties, therefore, whether any particular polymer will solubilize a specific drug is not necessarily predictable." While this general statement is true, the unpredictability argument is considerably weakened by the highly specific and relevant teaching of US2002/0009494. A POSA is not blindly experimenting with "any particular polymer" but is instead guided by a prior art reference that specifically identifies HPMCAS and spray-drying as effective for solving the very problem of enhancing solubility and bioavailability for sparingly soluble compounds.

Conclusion

Based on the combination of U.S. Pat. No. 7,709,517 and US2002/0009494, the claims of US patent 12447128 directed to an amorphous solid dispersion of enzalutamide with HPMCAS, prepared by spray-drying to improve aqueous solubility and/or bioavailability, would likely be considered obvious to a person having ordinary skill in the art. The motivation to combine these references is clear: to address the known solubility challenges of enzalutamide and develop a more convenient solid oral dosage form, utilizing a proven technique for sparingly soluble drugs that explicitly mentions the specific polymer and manufacturing method. The expectation of success in achieving improved solubility and bioavailability would be reasonable.